Business Context and Reporting Period
Company: Deckers Outdoor Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003
Business Overview: The Company operates four reportable segments: Teva, Simple, and Ugg wholesale divisions, and a newly acquired catalog and internet retailing business. In November 2002, the Company acquired worldwide Teva assets, eliminating royalty payments and adding direct-to-consumer retail operations.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Net Sales | $36,102,000 | $33,259,000 |
| Gross Profit | $16,240,000 | $15,114,000 |
| Gross Margin | 45.0% | 45.4% |
| Operating Income | $8,087,000 | $3,714,000 |
| Net Income | $4,203,000 | ($6,811,000) Loss |
| Diluted EPS | $0.37 | ($0.70) Loss |
| Cash from Operations | $3,809,000 | ($2,920,000) Used |
| Cash and Equivalents (End) | $4,769,000 | $12,966,000 |
| Total Debt (Current + Long-term) | $36,258,000 | N/A (Not explicitly totaled in text) |
| Working Capital | $24,220,000 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.5% to $36.1 million, driven by a 6.3% increase in Teva wholesale sales and a 200.4% surge in Ugg wholesale sales. Simple wholesale sales declined 24.7% due to retail environment challenges.
- Profitability Surge: Operating income more than doubled to $8.1 million. This was primarily due to the elimination of $2.33 million in Teva royalty and license costs following the acquisition, alongside reduced marketing expenses and bad debt provisions.
- Turnaround from Loss: The Company reported net income of $4.2 million compared to a net loss of $6.8 million in Q1 2002. The prior year loss included a non-cash goodwill impairment charge of $8.97 million related to the adoption of SFAS 142.
- Interest Expense: Net interest expense increased to $1.1 million from net interest income of $17,000 in the prior year, reflecting increased borrowings to finance the Teva acquisition.
- Segment Performance: Teva operating income rose to $11.0 million. The new Catalog/Internet segment contributed $113,000 in operating income.
Guidance, Outlook, and Risks
Management Guidance
- Fiscal 2003 Sales: Expected to range from $103 million to $107 million.
- Fiscal 2003 Diluted EPS: Expected to range from $0.50 to $0.53.
- Q2 2003 Sales: Expected to range from $23 million to $24 million.
- Q2 2003 Diluted EPS: Expected to range from $0.10 to $0.11.
- Brand Sales Targets (2003): Teva ($68M-$70M), Simple ($11M-$12M), Ugg ($24M-$25M).
Risks and Contingencies
- Seasonality: Sales are highly seasonal; Teva peaks in Q1/Q2, while Ugg peaks in Q4. Weather conditions significantly impact demand.
- Legal Proceedings: Litigation with a former European distributor in the Netherlands; maximum exposure estimated at $550,000 beyond current reserves.
- Trade Duties: Potential exposure to European anti-dumping duties on footwear from China/Indonesia. A reserve of $500,000 is maintained.
- Guarantees: The Company guarantees up to $1.0 million of an officer's bank loan and up to $450,000 of a third-party factory's payables.
- Liquidity: The Company maintains a $20 million revolving credit facility with $18.1 million available as of March 31, 2003.
Investor Verification Checklist
- Acquisition Impact: Verify the sustainability of operating margin improvements following the elimination of Teva royalties.
- Ugg Growth: Assess whether the 200% sales increase in Ugg is sustainable or driven by temporary celebrity exposure and inventory availability.
- Simple Brand Decline: Investigate the causes of the 24.7% drop in Simple wholesale sales and the effectiveness of turnaround strategies.
- Debt Servicing: Monitor cash flow sufficiency given the increase in interest expense and the $36.3 million total debt load.
- Legal Exposure: Track the status of the Netherlands distributor litigation and the European anti-dumping duty appeal.
- Seasonal Weather Risk: Evaluate the potential impact of unseasonable weather on Q2 Teva sales and Q4 Ugg sales.